I think there was a paper discussed here sometime back where it was determined that lifespan studies in lower lifeforms like worms and flies don’t correlate well with mammal lifespan studies.
Which to me is not reverent, the FDA is NOT the bastion of knowledge in medical compounds.
They the FDA hinder more than help, the real fact it is all about money with FDA .
Rapamycin
Lithium Orotate
Trametinib
Are in my sites, when I finish the DAV course.
“If you wait until you are ready, it is almost certainly too late.”
~Seth Godin
“Keep waiting till you are ready and your time waiting will be gone forever. You will never get that time back.” ~Joseph
"Which to me is not reverent, the FDA is NOT the bastion of knowledge in medical compounds.They the FDA hinder more than help, the real fact it is all about money with FDA.
And I support the right of an individual to make his own choices regarding his personal health and the medications he buys. And if you decide to proceed, I hope it works out for you.
With that said, this is a discussion forum. And I think most people here would agree that quality of evidence, cost, and risk/benefit ratios are all important considerations before adding a new compound to one’s antiaging regimen. For me, this medication wouldn’t satisfy any of these criteria. At standard dosages, almost half of patients become anemic. Elevated AST and hypoalbuminemia occur in 60 and 42%, respectively, suggesting liver toxicity. Neutropenia occurs in 44% of patients. And leukopenia occurs in 38%. And the list goes on. It’s one of those medications where, if you’re going to take it, you’d better have a damn good reason for doing so. And then careful monitoring and management of these adverse effects if they do occur.
Additionally, the primary reason for considering it for longevity purposes appears to be a fruit fly study. I have very little interest in drosophila and C. Elegans studies to begin with. They may provide starting points for research ideas in mice, but longevity findings in these organisms often fail to extend to higher organisms. And lastly, it’s very expensive.
In organisms ranging from invertebrates to mammals, reducing the activity of the nutrient-sensing mechanistic target of rapamycin (mTOR) and insulin/insulin-like growth factor signaling (IIS) network can promote longevity and health during aging (2, 3).
Lowering network activity can also protect against the pathology associated with genetic models of age-related diseases (1, 2). The network contains many drug targets, including mTOR, mitogen-activated protein kinase kinase (MEK), and glycogen synthase kinase-3 (GSK-3) (Fig. 1A).
Down-regulation of mTOR activity by rapamycin, GSK-3 by lithium, or MEK by trametinib can each individually extend lifespan in laboratory organisms (5–11),
and brief inhibition of mTOR has recently been shown to increase the response of elderly people to immunization against influenza (12). In addition, both mTOR and MEK inhibitors have been shown to reduce senescent phenotypes in human cells (13),
while increasing concentrations of lithium levels in drinking water correlate with reduced all-cause mortality in a Japanese population (10).
So mTOR inhibition, MEK inhibition, and lithium supplementation is the approach.
I would have preferred buying a few grams from a reliable Chinese supplier and then having it third-party tested. The drug has high oral bioavailability.
So I’m very interested in all this, particularly a lithium-rapa combo since my studies show the main issue with rapa and cancer is ubiquination mediated by GSK-3 preventing mtor inhibition in cancer.
However, I’m very wary of MEK inhibitors as I started taking dihydromyricetin high dose (2 grams) in January of this year and it seemed to cause profound skin aging effects that are only recently starting to go away.
I took dihydromyricetin years ago and didn’t have these problems.
I’m still wary of lithium until more research.
But all these molecules have long history of supplementation so like with many things - it appears the dose makes the poison.
